C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...Find More
Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...Find More
HPV (Human papillomavirus) is a very commonly found virus and most people have experienced it at some point in their lives. There are almost 200 different strains that can be split into low risk and high risk. Low-risk HPV usually doesn’t cause many problems, it usually causes conditions like genital warts. Whereas...Find More
In the year 2000, the first-ever Antibody-drug Conjugate (ADC) - Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market - Adectr...Find More
Merck, Gilead to co-develop combined HIV treatments Merck and Gilead have announced a collaboration to investigate Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen. Both...Find More
Cervical cancer is the fourth most common type of cancer and the fourth leading cause of death in women. The year 2018 reported approximately 570 000 cases of cervical cancer. And 311 000 women died from the tumor. According to the Cervical Cancer Market report by DelveInsight, cervical cancer incidence by 2020...Find More
Cervical cancer is the fourth most commonly diagnosed cancer in women after breast cancer, colorectal cancer, and lung cancer. Although Cervical cancer rates vary geographically, several studies have demonstrated an incommensurably high prevalence in developing nations. Of all the cases recorded in 2018 world...Find More
Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer, and in 2018 was estimated to be responsible for 9.6 million deaths. Costing people quality of lives and eventually lea...Find More
Ladies, January is the month of raising awareness about cervical cancer. In the US, 250000 women are affected every year. One can refrain from the cancer by avoiding human papillomavirus, or HPV, which is sexually transmitted. We can eliminate cervical cancer as a public health problem through intensified vaccinati...Find More
Cervical cancer remains one of the leading causes of cancer-related deaths worldwide. A recent publication in nature reported the extensive molecular characterization of 228 primary cervical cancers, and has been dubbed as the largest comprehensive genomic study of cervical cancer to date. The authors observed strik...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.